
Sep 22, 2026
AGIO Maintained by B of A Securities -- Price Target Raised to $50
B of A Securities has maintained a "Buy" rating for Agios Pharmaceuticals (AGIO) and increased its price target from $46.00 to $50.00. While GuruFocus indicates AGIO is significantly undervalued based on its GF Value, the company faces profitability challenges and has a low GF Score of 46/100, alongside recent insider selling activity. Investors are advised to exercise caution due to these mixed signals.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish